Home/Paper Details

Archive

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

A PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENT WITH DIABETES MELLITUS GETTING CHEMOTHERAPY AND CORTICOSTEROID

Open Access
Journal Type:Case Report
Subject Field:Internal Medicine
Downloads:455
Publish Date:June 21, 2024 8:00 pm
Views:344
Volume:151, Issue: 1, June, 2024
Subject:Medicine, Health & Food
Pages:196-204

Abstract

Primary Central Nervous System Lymphoma (PCNSL) is a rare form of aggressive extranodal non-Hodgkin's lymphoma. Treatment modalities for PCNSL cases have developed in the last few decades, with no universally-agreed consensus regarding the optimal treatment regimen to date. We report a 61-year-old patient with right limb weakness, decreased consciousness, and a history of recurrent seizures. The patient had a MSCT examination on the head, with and without contrast, showing an enhancing solid mass with perifocal edema around it in the right frontal lobe. On immunohistochemical histopathological examination of cerebral material, the conclusion was Non-Hodgkin Lymphoma B cell type high grade. The patient was diagnosed with Non-Hodgkin Lymphoma Cerebral B cell type high grade. The patient was subjected to chemotherapy with HD-MTX (high-dose methotrexate) and rituximab therapy for 6 cycles, in combination with dexamethasone. Chemotherapy evaluation after 6 cycles showed a complete response to therapy without any drug side effects from chemotherapy with consciousness returning to normal and limb weakness gradually improving.

© 2026 International Journal of Research Publications (IJRP). All rights reserved.